Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Agios, Celgene Target Accelerated Approvals For Precision AML Medicines

Sep 09 2016

• By Mandy Jackson

GoldKeyInPuzzle_1200x675

Related Content

BioNotebook: Emergent/Cangene, Sprout, Agios/Celgene, Sutro, Savient/Crealta

Dec 12 2013

Celgene and Agios to target cancer metabolism in $250 million deal

Apr 16 2010

ASH 2015: First-In-Class Myeloma Highlights

Dec 11 2015

Agios Gets $200m Up Front In New Celgene Deal, Regains AG-120 Rights

May 18 2016

Agios gains $20M to extend April cancer deal with Celgene

Oct 10 2011

Celgene, Agios extend collaboration as AG-221 impresses at ASH 2014

Dec 09 2014

Related Companies

Bristol Myers Squibb Company

Agios Pharmaceuticals, Inc.

Additional Topics

Commercial Regulation Cancer BioPharmaceutical

More from Business

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window